Metrics as of 10/15/2026, 08:20 AM (Berlin time), refresh in progress.
Pyxis Oncology Stock
Pyxis Oncology, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- Thomas Civik
- Employees
- 56
- Market cap
- $113 M
- IPO
- 08/10/2021
Pyxis Oncology, Inc. operates as a preclinical biopharmaceutical company focused on developing novel therapeutic approaches to combat various forms of cancer. Its investigational immune-oncology pipeline includes PYX-106, a fully human immunoglobulin G1 (IgG1) antibody designed to target siglec-15, which is being…
Pyxis Oncology stock: price history
1D
-3.2%
1W
-10.9%
1M
-47.8%
6M
+4.7%
YTD
+55.7%
1Y
-44.6%
2Y
-43.9%
5Y
-84.8%
10Y
–
Next earnings date
Next earnings date
02/11/2026 (in 16 days)
Volatility around earnings
~5% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 13/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about Pyxis Oncology
Analyst assessment of Pyxis Oncology
PRICE TARGET LOW
US$7.00
CONSENSUS
US$7.67
MEDIAN
US$8.00
PRICE TARGET HIGH
US$8.00
0
STRONG BUY
10
BUY
2
HOLD
0
SELL
0
STRONG SELL
12
TOTAL · Buy
As of: 10/09/2026
Pyxis Oncology stock metrics
P/E
-1.27
P/B
10.01
EV/EBITDA
-1.35
RETURN ON EQUITY
-221.6%
NET MARGIN
0.0%
DEBT/EQUITY
1.56
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
58.8%
FLOAT SHARES
37,251,756
AVG. DAILY VOLUME (30D)
1,320,868
Insider transactions (SEC)
GordonMD Global Investments LP
Dupont Jakob
Dupont Jakob
Institutional holders
Comparable stocks
Frequently asked questions about Pyxis Oncology stock
What does Pyxis Oncology do?
Pyxis Oncology, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is Thomas Civik, the company employs around 56 people.
The IPO was on 08/10/2021; the stock trades on NASDAQ under the ticker PYXS.
What do analysts say about Pyxis Oncology stock?
12 analysts rate the stock, the consensus is Buy (as of 10/09/2026).
The average price target is US$7.67, ranging from US$7.00 to US$8.00, with a median of US$8.00.
This is an external assessment, not a statement by Market Jury.
When does Pyxis Oncology report next?
The next earnings date is 02/11/2026.
Around past earnings, price swings were roughly 5% stronger than usual.
Does Pyxis Oncology pay a dividend?
No, Pyxis Oncology currently does not pay a dividend.
Which stocks are comparable to Pyxis Oncology?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get Pyxis Oncology stock analyzed?
Clicking "Analyze stock" lets five strategies assess Pyxis Oncology against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.